COMMENTARY ARTICLE

Beyond partnerships: redefining cdmo-biotech collaboration in the age of complexity
Operational Chemistry: Making Biotech–CDMO Teams Actually Work

Introduction

As the landscape of therapeutic development rapidly evolves, so do the operating models that support it. The relationship between biotechs and Contract Development and Manufacturing Organizations (CDMOs) has fundamentally shifted—from transactional outsourcing arrangements to strategic co-execution frameworks. In an era marked by increased scientific complexity, shorter Funding cycles, and increased regulatory scrutiny, there is no room for misalignment.

Advanced modalities such as antibody-drug conjugates (ADCs), oligonucleotides, and mRNA-based therapies require seamless integration across analytical development, quality systems, regulatory readiness, and manufacturing execution. At the same time, policies like the BioSecure Act highlight the need for operational transparency, supply chain traceability, and mitigation of geopolitical risks.